Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral t-cell lymphomas: Results of a phase i study

Journal of Clinical Oncology

Volumn 32, Issue 28, 2014, Pages 3137-3143

  Fanale, Michelle A ^a   Horwitz, Steven M ^b   Forero Torres, Andres ^c   Bartlett, Nancy L ^d   Advani, Ranjana H ^e   Pro, Barbara ^g   Chen, Robert W ^f   Davies, Andrew ^k   Illidge, Tim ^l   Huebner, Dirk ^h   Kennedy, Dana A ⁱ   Shustov, Andrei R ^j  

^a UNIVERSITY OF TEXAS   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^g FOX CHASE CANCER CENTER   (United States)

^h TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

ⁱ Seattle Genetics   (United States)

^j UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^k UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^l UNIVERSITY OF MANCHESTER   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CAC10-VCMMAE;

ADULT; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED EMESIS; CHILL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DYSPNEA; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART FAILURE; HUMAN; LARGE CELL LYMPHOMA; LEUKOPENIA; LUNG EMBOLISM; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SENSORY NEUROPATHY; SEPTIC SHOCK; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; YOUNG ADULT; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG ADMINISTRATION; KAPLAN MEIER METHOD; LYMPHOMA, T-CELL, PERIPHERAL; METABOLISM; TREATMENT OUTCOME; VERY ELDERLY; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD30; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; IMMUNOCONJUGATES; KAPLAN-MEIER ESTIMATE; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; NAUSEA; PREDNISONE; TREATMENT OUTCOME; VINCRISTINE; VOMITING; YOUNG ADULT;

EID: 84907462330     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.2456     Document Type: Article

References (18)

1. Swerdlow SH, Campo E, Harris NL, et al: Chapter 11: Mature T- and NK-cell neoplasms, in Swerdlow SH, Campo E, Harris NL, et al (eds): WHO classification of tumours of haematopoietic and lymphoid tissues (ed 4). Lyon, France, International Agency for Research on Cancer, 2008, pp 269-319
2. Savage KJ, Harris NL, Vose JM, et al: ALKanaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 111:5496-5504, 2008
3. Vose J, Armitage J, Weisenburger D: International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 26:4124-4130, 2008
4. Savage KJ, Chhanabhai M, Gascoyne RD, et al: Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann Oncol 15:1467-1475, 2004
5. Simon A, Peoch M, Casassus P, et al: Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma: Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol 151:159-166, 2010
6. Pro B, Advani R, Brice P, et al: Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: Results of a phase II study. J Clin Oncol 30:2190-2196, 2012
7. Pro B, Advani RH, Brice P, et al: Three-year survival results from an ongoing phase 2 study of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Presented at the Am Soc Hematol Annual Meeting, New Orleans, LA, December 7-10, 2013
8. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
9. Cheson BD, Pfistner B, Juweid ME, et al: Revised response criteria for malignant lymphoma. J Clin Oncol 25:579-586, 2007
10. Gallamini A, Zaja F, Patti C, et al: Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: Results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110:2316-2323, 2007
11. Kluin-Nelemans HC, van Marwijk Kooy M, Lugtenburg PJ, et al: Intensified alemtuzumab- CHOP therapy for peripheral T-cell lymphoma. Ann Oncol 22:1595-1600, 2011
12. d'Amore F, Relander T, Lauritzsen GF, et al: Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 30:3093-3099, 2012
13. Mercadal S, Briones J, Xicoy B, et al: Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma. Ann Oncol 19:958-963, 2008
14. Reimer P, Rüdiger T, Geissinger E, et al: Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: Results of a prospective multicenter study. J Clin Oncol 27:106-113, 2009
15. Rodriguez J, Conde E, Gutierrez A, et al: Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: A prospective study from The Gel-Tamo Study Group. Eur J Haematol 79:32-38, 2007
16. Corradini P, Tarella C, Zallio F, et al: Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation. Leukemia 20:1533-1538, 2006
17. O'Connor OA, Pro B, Pinter-Brown L, et al: Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: Results from the pivotal PROPEL study. J Clin Oncol 29:1182-1189, 2011
18. Piekarz RL, Frye R, Prince HM, et al: Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117:5827-5834, 2011.